Repositorio Dspace

Third Allogeneic Stem Cell Transplantation in Children: A Multicenter Analysis From the Spanish GETH-TC Pediatric Group

Mostrar el registro sencillo del ítem

dc.contributor.author Sisinni, Luisa
dc.contributor.author Vinagre-Enriquez, Sara
dc.contributor.author Villalón-Herrera, Marta
dc.contributor.author Plaza-Fornieles, Mercedes
dc.contributor.author López-Torija, Ivan
dc.contributor.author Urtasun-Erburu, Andrea
dc.contributor.author Alonso-García, Laura
dc.contributor.author García, Alexandra-Regueiro
dc.contributor.author Trabazo-del-Castillo, María
dc.contributor.author Bardon-Cancho, Eduardo-J
dc.contributor.author Leon-Triana, Odelaisy
dc.contributor.author Miñarro-Chacón, Carla
dc.contributor.author Fuster-Soler, José-Luis
dc.contributor.author Pérez-Martínez, Antonio
dc.contributor.author Balsalobre-López, Pascual
dc.contributor.author González-Vicent, Marta
dc.contributor.author Díaz-de-Heredia, Cristina
dc.date.accessioned 2026-08-03T10:29:12Z
dc.date.available 2026-08-03T10:29:12Z
dc.date.issued 2026-05-12
dc.identifier.issn 0902-4441
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/27215
dc.description.abstract Third allogeneic hematopoietic stem cell transplantation (HSCT3) is rarely performed in pediatric patients and is associated with high toxicity and mortality. Data on outcomes in this setting remain scarce. We conducted a retrospective multicenter study within the Spanish GETH-TC Pediatric group including 29 children and adolescents who underwent HSCT3 between 2011 and 2024 for malignant (n = 21) or nonmalignant (n = 8) diseases. Patient-, disease-, and transplant-related variables were analyzed, and survival outcomes were estimated using Kaplan-Meier methods. Engraftment was achieved in 22 patients (75.8%). Grade III-IV acute GvHD occurred in 7% and chronic GvHD in 11%. Severe viral infections were frequent (48%), as were bacterial (34%) and fungal infections (21%). By day +100, TRM was 31%, and overall mortality at last follow-up was 66%, predominantly transplant-related. Estimated 12-month overall survival (OS) and event-free survival (EFS) were 39.5% and 32.7%, respectively. Outcomes differed by indication: patients with malignant diseases had limited survival, particularly when transplanted with measurable residual disease, whereas outcomes were more favorable in nonmalignant disorders, with a 12-month EFS of 50%. Survival was also associated with preserved performance status. HSCT3 in children remains a high-risk procedure. Meaningful survival is restricted to carefully selected patients and appears more achievable in nonmalignant indications.
dc.language.iso eng
dc.publisher WILEY
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.title Third Allogeneic Stem Cell Transplantation in Children: A Multicenter Analysis From the Spanish GETH-TC Pediatric Group
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42119601
dc.relation.publisherversion https://onlinelibrary.wiley.com/doi/10.1111/ejh.70218
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1111/ejh.70218
dc.journal.title EUROPEAN JOURNAL OF HAEMATOLOGY
dc.identifier.essn 1600-0609


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta